In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse

Drug Metabolism and Disposition

Volumn 25, Issue 10, 1997, Pages 1130-1136

  Chauret, Nathalie ^a   Gauthier, Annick ^b   Martin, Jean ^b   Nicoll Griffith, Deborah A ^b  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; CHLORZOXAZONE; COUMARIN ANTICOAGULANT; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; METHANOL; MICROSOME ENZYME; MONOCLONAL ANTIBODY; PHENACETIN; QUINIDINE; SOLVENT; SULFAPHENAZOLE; TESTOSTERONE; TOLBUTAMIDE; TRANYLCYPROMINE; TROLEANDOMYCIN;

ADULT; ANIMAL TISSUE; ARTICLE; CAT; DOG; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HORSE; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

ADOLESCENT; ADULT; ANIMALS; CATS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; ENZYME INHIBITORS; HORSES; HUMANS; MICROSOMES, LIVER; MIDDLE AGED;

ANIMALIA; CANIS FAMILIARIS; EQUUS CABALLUS; FELIS CATUS;

EID: 0030812882     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. F. P. Guengerich: Characterization of human cytochrome P450 enzymes. FASEB J. 6, 745-748 (1942).
2. S. A. Wrighton, M. Vandenhranden, J. C. Stevens, L. A. Shipley, B. J. Ring, A. E. Rettie, and J. R. Cashman: In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25, 453-484 (1993).
3. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerieh: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
4. S. A. Wrighton and J. C. Stevens: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 1-21 (1992).
5. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. Vandenbranden: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2CI9 and S-mephenytoin 4'-hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
6. R. Peter, R. Bocker, P. H. Beaune, M. Iwasakim F. P. Guengerieh, and C. S. Yang: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3, 566-573 (1990).
7. J. R. Halpert, F. P. Guengerich, J. R. Bend, and M. A. Correia: Selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol. 125, 163 175 (1994).
8. . D. Sesardic, A. R. Boobis, B. P. Murray, S. Murray, J. Segura, R. de la Torre, and D. S. Davies: Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br. J. Clin. Pharmacol. 29, 651-663 (1990).
9. A. D. Rodrigues: Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochem. Pharmacol. 48, 2147-2156 (1994).
10. T. Inaba, M. Jurima, W. A. Mahon, and W. Kalow: In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytion p-hydroxylase and sparteine monooxygenase. Drug Mateb. Dispos. 13, 443-448 (1985).
11. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evafuation of specificities in the the vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
12. J. E. Sharer, L. A. Shipley, M. R. Vandenbranden, S. N. Binkley, and S. A. Wrighton: Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drus Metab. Dispos. 23, 1231-1241 (1995).
13. K. Sakamoto, S. Kirita, T. Baba, Y. Nakamura, Y. Yamazoe, R. Kato, A. Takanaka, and T. Matsubara: A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: purification. cDNA cloning and enzyme characterization. Arch. Biochem. Biophys. 319, 372-382 (1995).
14. A. Nakamura, Y. Yamamoto, T. Tasaki, C. Sugimoto, M. Masuda, A. Kazusaka, and S. Fujita: Purification and characterization of a dog cytochrome P450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody. Drug Metab. Dispos. 23, 1268-1273 (1945).
15. K. Ohta, M. Motoya, M. Komori, T. Miura, M. Kitada, M. Nagao, and T. Kamataki: Interspecies homology of cytochrome P450: purification and toxicological significance of a high spin form of P450 (P450-D2) from liver microsomes of polychlorinated biphenyl (PCB)-treated beagle dogs. J. Biopharm. Sci. 1,59-71 (1990).
16. T. Uchida, M. Komori, M. Kitada, and T. Kamataki: Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated beagle dogs. Mol. Pharmacol. 38, 644-651 (1990).
17. T. Shiraga, K. Iwasaki, K. Nozaki, T. Tamura, Y. Yamazoe, R. Kato, and A. Takanaka: Isolation and characterization of four cytochromes P450 isozymes from untreated and phenobarbital-treated beagle dogs. Biol. Pharm. Bull. 17, 22-28 (1994).
18. P. J. Ciaccio, P. E. Graves, D. P. Bourque, B. Glinsmann-Gibson, and J. R. Halpert: cDNA and deduced amino acid sequences of a dog liver cytochrome P-450 of the IIIA gene subfamily. Biochem. Biophys. Acta 1088, 319-322 (1991).
19. R. A. Yean and D. Gerken: Hepatic drug metabolism in vitro in the horse. Biochem. Pharmacol. 20, 3219-3221 (1971).
20. G. Martinez-Zedillo, C. Castilho-Alonso, V. M. Magdaleno, and A. Gonzalez-Angulo: Cytochrome P-450 and parathion metabolism in the fetal and adult gonads of the horse. Life Sci. (Washington D.C.) 25, 327-332 (1979).
21. M. Komori, A. Higami, Y. Imai, S. Imaoka, and Y. Funae: Purification and characterization of a form of P450 from horse liver microsomes. J. Biochem. 114, 445-448 (1993).
22. R. Pearce, D. Greenway, and A. Parkinson: Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch. Biochem. Biophys. 298, 211-225 (1992).
23. B. C. Eberhart, B. Gemzik, M. R. Halvorson, and A. Parkinson: Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol. Pharmacol. 40, 859-867 (1991).
24. A. Y. Lu and W. Levin: Partial purification of cytochromes P-450 and P-448 from rat liver microsomes. Biochem. Biophys. Res. Commun. 46, 1334-1339 (1972).
25. O. H. Lowry, N. J. Rosebrough, A. L. Fair, and R. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265- 275 (1951).
26. W. Tassaneeyakul, D. J. Birkett, M. H. Veronese, M. H. McManus, R. H. Tukey, L. C. Quattrochi, H. V. Gielboin. and J. O. Miners: Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265, 401-407 (1992).
27. P. J. Creaven, D. V. Parke, and R. T. Williams: A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomes. Biochem. J. 96, 390-398 (1965).
28. J. O. Miners, K. J. Smith, R. A. Robson, M. F. McManus, M. H. Veronese, and D. J. Birkett: Tolbutamide hydroxylation by human liver microsomes: kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 37, 1137-1144 (1988).
29. S. D. Hall, F. P. Guengerich, R. A. Branch, and G. R. Wilkinson: Characterization and inhibition of mephenytion-4 hydroxylase acitivity in human liver microsomes. J. Pharmacol. Exp. Ther. 240, 216-222 (1987).
30. U. T. Meier, T. Kronbach, and U. A. Meyer: Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal. Biochem. 151, 286-291 (1985).
31. T. Kronbach, D. Mathys, J. Gut, T. Catin, and U. A. Meyer: High- performance liquid Chromatographic assays for bufuralol-1'-hydroxylase. debrisoquine-4-hydroxyalse, and dextromethorphan-O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem. 162, 24-32 (1987).
32. A. J. Sonderfan, M. P. Arlotto, D. R. Dutton, S. K. McMillen, and A. Parkinson: Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 255, 27-41 (1987).
33. J. H. Zarr: "Biostatistical Analysis," 2nd ed., Prentice-Hall, Englewood Cliffs, NJ. 1984.
34. D. Sesardic, A. R. Boobis, R. J. Edwards, and D. S. Davies: A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br. J. Clin. Pharmacol. 26, 363-372 (1988).
35. T. Yasumori, L. Chen, K. Nagata, Y. Yamazoe, and R. Kato: Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J. Pharmacol. Exp. Ther. 264, 89-94 (1993).
36. A. J. Sonderfan and A. Parkinson: Species differences in the hydroxylation of testosterone by liver microsomes. Toxicology 8, 226 (1988).
37. T. Niwa, H. Kaneko, Y. Naritomi, A. Togawa, T. Shiraga, K. Iwasaki, Z. Toszuka, and T. Hata: Species and sex differences of testosterone and nifedipine oxidation in liver microsomes of rat, dog and monkey. Xenobiotica 25, 1041-1049 (1995).
38. K. L. Kunze and W. F. Trager: Isoform-sclective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656 (1993).
39. P. Soucek and I. Gut: Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenabiotica 22, 83-103 (1992).
40. V. Nedelcheva and I. Gut: P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 24, 1151-1175 (1994).
41. S. Kobayashi, S. Murray, D. Watson, D. Sesardic, D. S. Davies, and A. R. Boobis: The specificity of inhibition of debrisoquine4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem. Pharmacol. 38, 2795-2799 (1989).
42. P. J. Ciaccio and J. R. Halpert: Characterization of a phenobarbital inducible dog liver cytochrome P450 structurally related to rat and human enzymes of the P450IIIA (steroid inducible) gene subfamily. Arch. Biochem. Biophys. 284, 284-299 (1989).